Vyleesi (Bremelanotide) Overdose and Accidental Excess Dose: What to Know

How Bremelanotide Works and Why Overdose Presents Specific Risks

Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors, primarily MC4R, in the central nervous system. Sexual desire in premenopausal women involves dopaminergic and melanocortinergic pathways in the hypothalamus and limbic system, and bremelanotide modulates these circuits without directly affecting hormones like estrogen or testosterone 1. The drug received FDA approval in June 2019 based on the RECONNECT program, two replicate phase 3 trials enrolling 1,247 premenopausal women with HSDD 2.

Because MC4R activation also controls melanogenesis, blood pressure, and gastrointestinal motility, an excess dose amplifies each of these off-target effects in a dose-dependent pattern. The 1.75 mg dose was chosen specifically because higher doses in phase 2 studies (up to 4 mg) produced unacceptable nausea rates without meaningfully greater efficacy 3. This dose-response ceiling is relevant to overdose assessment: the margin between the therapeutic and poorly tolerated dose is narrow, but the margin between the therapeutic dose and a dangerous dose appears wider.

Symptoms Expected After an Accidental Excess Dose

The most predictable symptom of bremelanotide overdose is nausea. At the approved 1.75 mg dose, 40.0% of participants in RECONNECT reported nausea compared to 1.3% on placebo 1. In dose-ranging studies, nausea at 4 mg was both more frequent and more severe, with some participants experiencing emesis 3.

Other dose-dependent adverse effects include flushing (reported in 20.3% at the approved dose), injection-site reactions, headache, and a transient rise in blood pressure. The FDA label notes that bremelanotide 1.75 mg increases systolic blood pressure by approximately 6 mmHg and diastolic pressure by approximately 3 mmHg, with peak effects occurring around 2 to 3 hours post-dose and resolving within 12 hours 2. An excess dose could amplify this pressor response, which matters for patients with uncontrolled hypertension or cardiovascular disease. Bremelanotide is contraindicated in uncontrolled hypertension for this reason.

Skin darkening (hyperpigmentation) is a class effect of melanocortin agonists. In clinical trials, hyperpigmentation appeared in roughly 1% of bremelanotide-treated patients, most commonly on the face, gingiva, and breasts, and it was more likely with repeated dosing at higher-than-approved frequencies 2. A single large excess dose may or may not trigger visible pigmentation, but repeated overdosing raises this risk substantially.

No Antidote Exists: Management Is Supportive

There is no specific reversal agent for bremelanotide. The drug's relatively short half-life of approximately 2.7 hours means that a single excess dose will clear from systemic circulation within 12 to 14 hours 2. Management of a suspected overdose follows standard supportive care principles.

For nausea and vomiting, ondansetron (4 to 8 mg orally or intravenously) is a reasonable first-line antiemetic. The FDA label specifically notes that nausea typically begins within 45 minutes of injection and resolves within 2 hours at the approved dose. For blood pressure elevation, continuous monitoring is appropriate if the patient has pre-existing cardiovascular risk factors. Short-acting antihypertensives may be considered if systolic blood pressure exceeds 180 mmHg or diastolic exceeds 120 mmHg, though published case reports of hypertensive crisis from bremelanotide alone have not been documented in the medical literature as of this writing.

The American Association of Poison Control Centers (1-800-222-1222) should be contacted for any case where more than one autoinjector has been administered within a 24-hour window or where a patient reports symptoms beyond mild nausea and flushing 4.

Dose Limits the FDA Set and Why They Matter for Overdose Risk

The FDA-approved labeling for bremelanotide specifies three dosing constraints: no more than 1.75 mg per injection, no more than one injection per 24 hours, and no more than 8 doses per calendar month 2. Each constraint addresses a different safety concern.

The per-dose limit reflects the phase 2 dose-finding data. In a study by Clayton et al. (2016), doses of 0.75 mg, 1.25 mg, and 1.75 mg were compared. The 1.75 mg dose provided the greatest improvement in satisfying sexual events (SSEs), with a mean increase of 0.7 SSEs per month over placebo, while higher doses did not add benefit 3. The 24-hour interval limit accounts for bremelanotide's pharmacokinetics: with a half-life of 2.7 hours, five half-lives (complete clearance) require approximately 13.5 hours, so a 24-hour window provides ample margin. The monthly cap of 8 doses addresses cumulative melanocortin receptor stimulation and the risk of progressive skin hyperpigmentation.

A patient who inadvertently uses two autoinjectors in rapid succession has effectively taken 3.5 mg, a dose that was studied (the 4 mg arm) in phase 2 trials. While not tested as a safety endpoint in phase 3, the phase 2 data provide some reassurance that a one-time double dose is unlikely to produce effects beyond severe nausea and a larger blood pressure spike 3.

Cardiovascular Considerations in Overdose

The transient blood pressure increase is the most clinically significant concern in bremelanotide overdose. The FDA's review of the RECONNECT data showed that among patients with a baseline systolic blood pressure <140 mmHg, the mean increase at 1.75 mg was 6 mmHg systolic and 3 mmHg diastolic 2. Blood pressure returned to baseline within 12 hours in most subjects.

The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction note that "melanocortin agonists carry a pressor effect that clinicians should monitor, particularly in women with metabolic syndrome or pre-existing hypertension" 5. For an overdose scenario, this means checking blood pressure at presentation and again at 2 to 3 hours post-ingestion (peak effect window). A 12-lead ECG is reasonable if the patient reports chest discomfort or palpitations, though bremelanotide has not been associated with QTc prolongation in thorough QT studies at doses up to 10 mg administered intranasally 2.

Patients currently taking antihypertensive medications or those with known cardiovascular disease warrant a longer observation period. The FDA label recommends against use in patients with uncontrolled hypertension or known cardiovascular disease, so any overdose in these populations deserves emergency department evaluation regardless of symptom severity.

Differentiating Overdose From Expected Side Effects

Many of the symptoms a patient might attribute to overdose are, in fact, expected pharmacologic effects at the standard dose. Nausea occurs in 4 out of 10 treated patients. Flushing occurs in 1 out of 5. Headache affects roughly 11% 1. The distinction between a side effect and an overdose reaction comes down to dose confirmation, timing, and severity.

Questions to ask a patient who presents with suspected overdose: How many autoinjectors did you use? How far apart? Have you used bremelanotide before, and did you experience nausea at the standard dose? A first-time user experiencing severe nausea at 1.75 mg does not have an overdose. She has a common adverse reaction. A patient who used two autoinjectors within an hour has a genuine excess-dose exposure.

The prescribing information for Vyleesi also notes that approximately 13% of patients in RECONNECT discontinued treatment due to adverse events, with nausea being the most common reason 2. Severe nausea alone, even at the approved dose, does not necessarily indicate overdose.

Hyperpigmentation: The Cumulative Overdose Risk

Unlike nausea and blood pressure changes, which are acute effects, hyperpigmentation represents a cumulative risk from repeated excess dosing. Bremelanotide activates MC1R on melanocytes, stimulating melanin production 6. In the phase 3 RECONNECT trials, focal skin darkening was reported in 1% of participants using the drug as directed. The pigmentation was most often mild and appeared on sun-exposed areas of the face, on the gums, and around the areolae.

The concern with chronic over-use is that melanocortin-driven pigmentation may not fully reverse after discontinuation. The FDA label states that resolution of hyperpigmentation was not confirmed in all affected participants at the time of approval 2. For patients who have been exceeding the 8-dose monthly limit, a dermatologic evaluation is appropriate. Wood's lamp examination can help distinguish epidermal from dermal melanin deposition, which informs prognosis for resolution.

When to Go to the Emergency Department

Not every case of accidental excess dosing requires emergency care. A practical triage framework:

Go to the ED if the patient used more than two autoinjectors (more than 3.5 mg) within 24 hours, has uncontrolled hypertension or known cardiovascular disease, develops systolic blood pressure above 180 mmHg, experiences chest pain or syncope, or has persistent vomiting that prevents oral hydration.

Monitor at home if the patient used two autoinjectors but has normal baseline blood pressure, is experiencing only nausea and flushing, and can tolerate oral fluids. She should check blood pressure every 30 minutes for 3 hours if a home monitor is available.

Call Poison Control (1-800-222-1222) for any case where the number of doses is uncertain or the patient is outside the premenopausal female population for whom the drug was studied (for example, a child who accessed an autoinjector or a male partner who self-injected) 4.

Bremelanotide Pharmacokinetics Relevant to Overdose Duration

Understanding how quickly bremelanotide clears the body helps set expectations. After subcutaneous injection, peak plasma concentration (Cmax) occurs at approximately 1 hour. The volume of distribution is approximately 123 L, indicating extensive tissue distribution 2. The drug is metabolized by hydrolysis into multiple peptide fragments, and renal clearance accounts for roughly 64% of elimination.

With a half-life of 2.7 hours, plasma levels drop below 10% of Cmax by approximately 9 hours post-injection. Symptoms from a single excess dose should therefore peak between 1 and 3 hours and largely resolve within 6 to 8 hours. If symptoms persist beyond 12 hours, re-evaluation is warranted, as this time course would be atypical for bremelanotide and may suggest an alternative diagnosis.

In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), the drug's half-life may be prolonged, and peak concentrations could be higher than expected. Bremelanotide has not been studied in dialysis patients, and it is unknown whether the drug is dialyzable given its molecular weight of 1,025 Da and protein binding of 21% 2.

Drug Interactions That Modify Overdose Risk

Bremelanotide slows gastric emptying. The FDA label includes a specific warning that co-administration with oral medications may reduce their absorption. This effect becomes clinically relevant in overdose for two reasons.

First, a patient who has taken oral naltrexone (used off-label for alcohol use disorder or as part of combination HSDD therapy) may experience delayed naltrexone absorption if bremelanotide was injected first. Second, any oral antiemetic given after bremelanotide injection may itself be subject to delayed absorption, which could reduce its effectiveness against bremelanotide-induced nausea. For this reason, intravenous ondansetron is preferable to oral formulations in a symptomatic overdose 7.

Bremelanotide does not undergo cytochrome P450 metabolism, so traditional drug-drug interactions at the CYP level are not a concern. The primary interaction pathway is pharmacodynamic: any concomitant drug that raises blood pressure (decongestants, stimulants, MAO inhibitors) could have an additive effect with bremelanotide's pressor response.

Pediatric and Unintended-Population Exposures

Bremelanotide is approved only for premenopausal women aged 18 and older. Accidental exposures in children or other populations outside the approved indication require immediate contact with Poison Control. There are no published pediatric pharmacokinetic or safety data for bremelanotide 2.

In preclinical studies, bremelanotide at doses 10 times the human equivalent caused decreased food intake in rodents, consistent with MC4R's known role in appetite regulation 6. A child exposed to a full 1.75 mg autoinjector (which represents a much higher mg/kg dose than in an adult) could theoretically experience more pronounced nausea, vomiting, and blood pressure changes. Supportive care with IV fluids and blood pressure monitoring would be appropriate.

For male adults who self-administer bremelanotide, whether intentionally or accidentally, the expected effects include nausea, flushing, and potentially penile erection (an MC4R-mediated effect documented in early male-focused clinical trials by Diamond et al.) 8. The blood pressure risks are identical regardless of sex.

Patients with hepatic impairment (Child-Pugh A or B) showed no clinically meaningful differences in bremelanotide exposure in pharmacokinetic studies, so dose adjustment is not required and overdose management does not differ in this population 2.